Research Summary Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19 DOI: 10.1056/NEJMdo007206 Save ...

The researchers found that with fluticasone furoate/vilanterol therapy, the rate of moderate or severe exacerbations was 8.4% lower than with usual care (P =.02).

The ACTIV-6 trial investigated the effectiveness of inhaled fluticasone furoate on mild-to-moderate COVID-19 cases and found it did not accelerate recovery or prevent clinical progression compared ...

The U.S. Food and Drug Administration approved once-daily Veramyst (fluticasone furoate) Nasal Spray to treat seasonal and year- round allergy symptoms in adults and children two years of age and ...

All participants underwent a 4-week run-in period with open-label fluticasone propionate (100 µg) twice daily before being randomly assigned 1:1 to 24 weeks of once-daily double-blind FF/VI (50/ ...

The Scottish Medicines Consortium has approved the use of GlaxoSmithKline’s Avamys (fluticasone furoate) – a once-daily nasal spray for the treatment of the symptoms of allergic rhinitis – on the ...

TGH and USF Health are taking part in the study, which will look at drugs (ivermectin, fluticasone furoate, and fluvoxamine) to see their impact on the omicron variant of COVID-19.